[Prophylactic efficacy of reaferon in viral hepatitis A and acute respiratory infections in children].
Reaferon, the analog of human alpha 2-interferon obtained by gene engineering techniques, was studied with a view to its use for the prevention of hepatitis A. The study involved children of preschool age in Tashkent. In a strictly controlled trial children aged 2-6 years received the preparation orally in a dose of 1 X 10(6) I. U. or the diluent alone used as placebo. The preparation was administered to 1,100 children and the placebo to 1,078 children. The preparation and placebo were administered twice a week for two months. On the whole, during that period hepatitis A morbidity in both test and control groups of children was the same (5.1% and 4.9% respectively), but among children of nursery age receiving Reaferon the incidence of hepatitis A and acute respiratory viral infections was lower than among those receiving the placebo, though this difference was statistically significant only for cases of acute respiratory infections.
Iuldashev
A K
AK
Slepushkin
A N
AN
Khodzhaeva
M A
MA
Schastnyĭ
E I
EI
Kamilov
F Kh
FKh
D000208:Acute Disease; D002675:Child, Preschool; D004341:Drug Evaluation; D006506:Hepatitis A / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010919:Placebos; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000517:prevention & control*; D012621:Seasons; D013997:Time Factors; D014610:Uzbekistan
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010919:Placebos; D011994:Recombinant Proteins
Izuchenie profilakticheskoĭ éffektivnosti reaferona pri virusnom gepatite A i ostrykh respiratornykh infektsiiakh u deteĭ.